$74.09
1.29% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Insmed Incorporated Stock price

$74.09
+3.13 4.41% 1M
+52.09 236.77% 6M
+43.10 139.08% YTD
+50.15 209.48% 1Y
+43.48 142.05% 3Y
+51.96 234.79% 5Y
+59.85 420.29% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.94 1.29%
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Key metrics

Market capitalization $13.25b
Enterprise Value $12.95b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 37.76
P/S ratio (TTM) P/S ratio 38.65
P/B ratio (TTM) P/B ratio 27.41
Revenue growth (TTM) Revenue growth 22.13%
Revenue (TTM) Revenue $342.96m
EBIT (operating result TTM) EBIT $-703.93m
Free Cash Flow (TTM) Free Cash Flow $-634.81m
Cash position $1.47b
EPS (TTM) EPS $-5.56
P/E forward negative
P/S forward 37.13
EV/Sales forward 36.28
Short interest 7.84%
Show more

Is Insmed Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Insmed Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Insmed Incorporated forecast:

18x Buy
100%

Analyst Opinions

18 Analysts have issued a Insmed Incorporated forecast:

Buy
100%

Financial data from Insmed Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
343 343
22% 22%
100%
- Direct Costs 83 83
27% 27%
24%
260 260
21% 21%
76%
- Selling and Administrative Expenses 397 397
29% 29%
116%
- Research and Development Expense 556 556
1% 1%
162%
-693 -693
6% 6%
-202%
- Depreciation and Amortization 11 11
46% 46%
3%
EBIT (Operating Income) EBIT -704 -704
5% 5%
-205%
Net Profit -864 -864
19% 19%
-252%

In millions USD.

Don't miss a Thing! We will send you all news about Insmed Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insmed Incorporated Stock News

Positive
Seeking Alpha
6 days ago
Insmed Incorporated's ARIKAYCE, approved for MAC lung disease, achieved strong revenue growth in Q3 of 2024 and potential for expanded FDA approval, boosting its market opportunity. Brensocatib's NDA filing for bronchiectasis is expected in Q4 2024 and could lead to a U.S. launch by mid-2025. Top-line results from the phase 2b study, using TPIP for the treatment of patients with PAH, expected i...
Neutral
PRNewsWire
19 days ago
BRIDGEWATER, N.J. , Nov. 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 27 new employees.
Neutral
PRNewsWire
20 days ago
BRIDGEWATER, N.J. , Nov. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference in Boston...
More Insmed Incorporated News

Company Profile

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Will Lewis
Employees 912
Founded 1988
Website www.insmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today